Drug Profile

Research programme: eicosapentaenoic acid based therapies - Amarin/Mochida Pharmaceutical

Alternative Names: EPA based therapies

Latest Information Update: 28 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amarin Corporation; Mochida Pharmaceutical
Class Cardiovascular therapies; Eicosanoids; Omega 3 fatty acids; Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jul 2022 No recent reports of development identified for research development in Cardiovascular-disorders in Ireland
28 Jul 2022 No recent reports of development identified for research development in Cardiovascular-disorders in Japan
12 Jun 2018 Amarin Corporation and Mochida Pharmaceuticals enter into an agreement to develop and commercialise drug products based on omega-3 fatty acid, eicosapentanoic acid in US and other territories

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com